Heart Failure Management Guidelines

Introduction to Heart Failure Management

• The American College of Cardiology recommends a staged, algorithmic approach to heart failure management, centered on four foundational medications: ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, titrated to target doses, with diuretics added for fluid management and device therapy considered in appropriate candidates 1

Staging-Based Treatment Algorithm

• The American Heart Association suggests aggressively controlling hypertension with target BP <130/80 mmHg if cardiovascular risk >10% in Stage A patients 2
• The American Family Physician recommends treating hyperlipidemia with statins to reduce incident heart failure risk by approximately 50% in Stage A patients 3
• Consider ACE inhibitors or ARBs in patients with atherosclerotic disease, diabetes, or hypertension in Stage A, as recommended by the American Family Physician and the American College of Cardiology 3, 1

Foundation Therapy for HFrEF

• The European Society of Cardiology recommends ACE inhibitor/ARB/ARNI as first-line therapy for mortality reduction in HFrEF patients, with titration to target doses over 2-4 weeks 1, 2
• The American College of Cardiology suggests adding beta-blocker to reduce mortality and hospitalizations in HFrEF patients, continuing during hospitalization unless hemodynamically unstable 1, 2
• The European Journal of Heart Failure recommends mineralocorticoid receptor antagonist (spironolactone) for patients with NYHA class II-IV and LVEF ≤35%, monitoring potassium and renal function closely to avoid hyperkalemia 4, 5, 1
• The American College of Cardiology recommends SGLT2 inhibitor for proven mortality benefit in both HFrEF and HFpEF patients 1, 2

Symptomatic Management

• The European Journal of Heart Failure suggests diuretics are essential when fluid overload manifests as pulmonary congestion or peripheral edema, using cautiously to avoid excessive diuresis 6, 1
• The American College of Cardiology recommends teaching flexible diuretic regimen based on daily weight monitoring 1

Device Therapy

• The American College of Cardiology recommends implantable cardioverter-defibrillator (ICD) for primary prevention in patients with LVEF ≤30-35%, NYHA class II-III on optimal medical therapy ≥3 months, life expectancy >1 year 2
• The American College of Cardiology suggests cardiac resynchronization therapy (CRT) with LVEF ≤35%, sinus rhythm, NYHA class II-IV, QRS ≥150 ms with left bundle branch block 2

Management of Acute Decompensation

• The American College of Cardiology recommends administering IV loop diuretics at doses equal to or exceeding chronic oral daily dose within 1 hour of presentation, and continuing ACE inhibitors and beta-blockers unless hemodynamically unstable 2
• The Journal of the American College of Cardiology suggests monitoring continuously for at least 24 hours: heart rate, rhythm, blood pressure, oxygen saturation, and scheduling early follow-up within 7-14 days and telephone follow-up within 3 days of discharge 7

Special Populations: Diastolic Heart Failure (HFpEF)

• The European Journal of Heart Failure recommends diuretics cautiously for fluid overload, avoiding excessive diuresis as diastolic dysfunction is highly preload-dependent, and considering ACE inhibitors to improve relaxation, reduce hypertrophy, control hypertension 4, 5, 8, 9
• The American College of Cardiology suggests beta-blockers to lower heart rate and increase diastolic filling period, and considering verapamil-type calcium antagonists to improve function, particularly in hypertrophic cardiomyopathy 4, 5, 8, 9

Lifestyle Modifications

• The American College of Cardiology recommends restricting sodium to <2-3 g/day and measuring weight daily at the same time, and avoiding excessive alcohol intake 2
• The European Journal of Heart Failure suggests regular physical activity in stable patients to prevent muscle deconditioning, and smoking cessation with nicotine replacement therapies if needed 6

Monitoring Requirements

• The American College of Cardiology recommends monitoring at each visit: symptoms, weight, blood pressure, heart rate, volume status, renal function, electrolytes, and considering natriuretic peptides (BNP or NT-proBNP) at baseline to guide therapy 2
• The American College of Cardiology suggests monitoring renal function and electrolytes regularly, especially after dose changes 1

Critical Pitfalls to Avoid

• The Journal of the American College of Cardiology recommends never using calcium channel blockers as treatment for heart failure, and never using long-term intermittent positive inotropic therapy 10
• The European Journal of Heart Failure suggests avoiding routine nutritional supplements (coenzyme Q10, carnitine) or hormonal therapies, and not adding ARB to ACE inhibitor plus beta-blocker combination 10, 4, 5

Multidisciplinary Approach

• The American College of Cardiology recommends implementing disease-management programs for high-risk patients to improve quality of life, reduce readmissions, and decrease costs, and patient education to explain heart failure mechanism, symptom recognition, self-weighing, medication adherence, and when to seek help 1, 2, 6

Heart Failure Management Guidelines

Introduction to Heart Failure Management

• The American College of Cardiology recommends initiating four foundational medication classes (ACE inhibitors/ARBs/ARNi, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors) rapidly and titrating to target doses in all patients with HFrEF, with SGLT2 inhibitors now recommended across the entire ejection fraction spectrum 11
• The American Heart Association emphasizes a revised staging system to emphasize prevention and early intervention, including aggressively controlling hypertension to target BP <130/80 mmHg if cardiovascular risk >10% 11

Staging and Prevention Framework

• The American College of Cardiology recommends a staging system with four stages: Stage A ("At Risk for HF"), Stage B ("Pre-HF"), Stage C (Symptomatic HF), and Stage D (Advanced HF), with corresponding treatment approaches 11
• For patients with structural heart disease but no symptoms (Stage B), the American College of Cardiology recommends continuing neurohormonal antagonists and monitoring closely for symptom development 11, 12

Heart Failure with Reduced Ejection Fraction (HFrEF)

• The American College of Cardiology recommends initiating all four medication classes rapidly—ideally within the first 3 months of diagnosis—and titrating to target doses over 2-4 weeks, not sequentially over months, for patients with HFrEF 11
• The American College of Cardiology recommends ARNi (sacubitril/valsartan) as an alternative to ACE inhibitors/ARBs in patients who remain symptomatic despite optimal therapy, with Class 2b recommendation 11

Heart Failure with Preserved Ejection Fraction (HFpEF)

• The American College of Cardiology recommends SGLT2 inhibitors for HFpEF with proven benefit, and optimal blood pressure control is a new performance measure with Class I recommendation 11, 13
• The American Heart Association recommends evidence of increased filling pressures is critical for diagnosis when LVEF >40%, obtained from noninvasive testing (natriuretic peptides, diastolic function on imaging) or invasive hemodynamic measurement 11

Advanced Heart Failure (Stage D)

• The American College of Cardiology recommends referring patients with advanced HF who wish to prolong survival to a HF specialty team for review of management, assessment for advanced therapies (LVAD, transplant), and palliative care including palliative inotropes where consistent with patient goals 11
• The American College of Cardiology recommends meticulous control of fluid retention is critical in end-stage HF, and patients may tolerate only small doses of neurohormonal antagonists or may not tolerate them at all due to risk of hypotension and renal insufficiency 14

Heart Failure Management Guidelines

Introduction to Heart Failure Management

• The American College of Cardiology recommends controlling all cardiovascular risk factors aggressively to prevent progression to structural heart disease in patients at risk for heart failure 15
• The American Heart Association suggests targeting blood pressure <130/80 mmHg if cardiovascular risk >10% in patients with hypertension, diabetes, or atherosclerotic disease 15, 16

Stage A: At Risk for Heart Failure

• The American College of Cardiology recommends using ACE inhibitors or ARBs in patients with hypertension, diabetes, or atherosclerotic disease to prevent heart failure 15, 16
• The American Heart Association suggests initiating statin therapy to reduce incident heart failure risk by approximately 50% in patients at risk for heart failure 15
• Maintaining normal weight (BMI <25 kg/m²) and regular physical activity (≥150 minutes/week moderate intensity) are recommended for patients at risk for heart failure 15
• Avoiding smoking and excessive alcohol is recommended for patients at risk for heart failure 15

Stage B: Pre-Heart Failure

• The American College of Cardiology recommends initiating neurohormonal blockade to prevent symptom development and reduce mortality in patients with structural disease but no symptoms 15
• The American Heart Association suggests using ACE inhibitors (or ARBs if ACE-intolerant) titrated to target dose for patients with LVEF ≤40% 15
• Beta-blockers (bisoprolol, carvedilol, or metoprolol succinate) are recommended for patients with LVEF ≤40% or post-MI 15
• Statin therapy is recommended for all patients with a history of MI or acute coronary syndrome 15

Stage C: Symptomatic Heart Failure

• The American College of Cardiology recommends initiating all four foundational medication classes rapidly—ideally within the first 3 months—and titrating to target doses over 2-4 weeks, not sequentially over months, for patients with symptomatic heart failure 15, 17
• The American Heart Association suggests using ACE inhibitors, ARBs, or ARNIs as the first pillar of GDMT for patients with symptomatic heart failure 15, 17
• Beta-blockers (carvedilol, metoprolol succinate, or bisoprolol) are recommended as the second pillar of GDMT for patients with symptomatic heart failure 15, 17
• Mineralocorticoid receptor antagonists (MRAs) are recommended as the third pillar of GDMT for patients with symptomatic heart failure and LVEF ≤35% 15, 17
• SGLT2 inhibitors are recommended as the fourth pillar of GDMT for patients with symptomatic heart failure, regardless of diabetes status 15

Device Therapy for HFrEF

• The American College of Cardiology recommends ICD for primary prevention in patients with LVEF ≤35%, NYHA class II-III on optimal medical therapy ≥3 months (≥40 days post-MI), and life expectancy >1 year 15, 17, 18
• Cardiac resynchronization therapy (CRT) is recommended for patients with LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms, and NYHA class II-IV on GDMT 15, 17, 18

Management of Acute Decompensated Heart Failure

• The American College of Cardiology recommends IV loop diuretics at doses equal to or exceeding chronic oral daily dose within 1 hour of presentation for patients with acute decompensated heart failure 18
• The American Heart Association suggests continuing ACE inhibitors and beta-blockers unless hemodynamically unstable in patients with acute decompensated heart failure 18

Comorbidity Management

• The American College of Cardiology recommends SGLT2 inhibitors for glycemic control and to reduce HF-related events in patients with type 2 diabetes 15
• The American Heart Association suggests uptitrating GDMT to maximally tolerated target doses rather than adding additional antihypertensives for patients with hypertension 15
• Iron deficiency should be treated with IV iron replacement (ferric carboxymaltose) for ferritin <100 ng/mL or 100-300 ng/mL with transferrin saturation <20% to improve functional status and quality of life in patients with heart failure 15, 19

Critical Pitfalls to Avoid

• The American College of Cardiology recommends avoiding calcium channel blockers (diltiazem, verapamil) as treatment for HFrEF 15
• The American Heart Association suggests avoiding long-term intermittent positive inotropic therapy and NSAIDs, which can cause acute kidney injury, hyperkalemia, and reduce antihypertensive efficacy in patients with heart failure 15, 18

Guideline‑Directed Pharmacologic Management of Hypertensive Systolic Heart Failure

Foundation Pharmacotherapy

• ACE inhibitors (or ARBs) are essential to lower cardiovascular mortality and heart‑failure hospitalization in patients with hypertensive systolic heart failure. (ACC/AHA guideline) 20
• If an ACE inhibitor causes cough or angio‑edema, substitution with an ARB is recommended. (ACC/AHA guideline) 21
• Beta‑blockers (carvedilol, metoprolol succinate, or bisoprolol) should be started in all hemodynamically stable patients to reduce mortality and hospital admissions. (ACC/AHA guideline) 20
• Mineralocorticoid‑receptor antagonists (spironolactone or eplerenone) are indicated for patients with NYHA class II–IV symptoms and LVEF ≤ 35 %, provided renal function is adequate and serum potassium is normal. (ACC/AHA guideline) 21

Diuretic Therapy

• Loop diuretics should be initiated at doses equal to or exceeding the patient’s chronic oral daily dose to achieve rapid decongestion in any patient with clinical signs of fluid overload. (ACC/AHA guideline) 20
• Thiazide‑type diuretics provide superior blood‑pressure control compared with loop diuretics but are less effective for volume removal in severe heart failure. (ACC/AHA guideline) 22

Blood‑Pressure Targets

• Target blood pressure is < 130/80 mmHg; in selected patients a more intensive goal of < 120/80 mmHg may be pursued. (ACC/AHA guideline) 22
• Most successful heart‑failure trials achieved systolic pressures between 110 mmHg and 130 mmHg, supporting these target ranges. (ACC/AHA guideline) 22
• The COPERNICUS trial, with a mean pretreatment pressure of 123/76 mmHg, demonstrated additional benefit from lower blood‑pressure targets. (ACC/AHA guideline) 22

Titration Strategy

• If hypertension persists after optimal dosing of ACE/ARB/ARNI, beta‑blocker, MRA, and SGLT2‑inhibitor therapy, a dihydropyridine calcium‑channel blocker (amlodipine or felodipine) may be added, especially when angina co‑exists. (European Society of Cardiology guideline) 23

Contraindicated Medications

• Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) are contraindicated because of negative inotropic effects and a heightened risk of heart‑failure worsening. (ACC/AHA guideline) 22
• Alpha‑blockers such as doxazosin increase the risk of developing heart failure by approximately two‑fold compared with thiazide diuretics. (ACC/AHA guideline) 22
• Clonidine and moxonidine should be avoided; moxonidine has been linked to increased mortality in heart‑failure patients. (ACC/AHA guideline) 22
• Long‑term intermittent positive inotropic therapy is not recommended in this population. (ACC/AHA guideline) 21

Special Considerations

• In elderly patients with wide pulse pressures, aggressive SBP lowering can produce diastolic pressures < 60 mmHg, necessitating careful monitoring for myocardial ischemia and worsening heart failure. (ACC/AHA guideline) 22
• When lowering blood pressure in patients with coronary artery disease, the reduction should be gradual and tachycardia avoided. (European Society of Cardiology guideline) 23

Lifestyle Recommendations

• Sodium intake should be limited to < 2–3 g per day, daily weight should be recorded at the same time each day, and a supervised exercise program should be instituted in stable patients. (ACC/AHA guideline) 22